Clinical Trials Browser

Immunoglobulin Light-chain Amyloidosis, Recurrence

NCT06963216 2026-05-11

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT05145816 2026-05-07

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

37 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Phase 3 Recruiting

338 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07448935 2026-05-06

ALPS

Recruiting

100 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, POEMS Syndrome

NCT07250269 2026-04-28

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Phase 1 Recruiting

9 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06649695 2026-04-21

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

Phase 2 Recruiting

30 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04839003 2026-04-16

ReAL

Recruiting

5,000 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06205953 2026-04-16

EUREKA

Recruiting

400 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06383143 2026-04-16

ProDigALIty

Recruiting

760 enrolled

Plasma cell

Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance

NCT05898646 2026-03-30

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Phase 2 Recruiting

96 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05444920 2026-03-27

ITA-WebNet

Recruiting

1,000 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07081646 2026-03-24

ALACRITY

Phase 1/2 Recruiting

91 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01408225 2026-03-23

B-SCR-MM

Recruiting

5,000 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Phase NA Recruiting

41 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Recruiting

50 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06569147 2026-03-06

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

49 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

Clinical Trials

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

ALPS

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

ReAL

EUREKA

ProDigALIty

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

ITA-WebNet

ALACRITY

B-SCR-MM

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Rapid dFLC Response Predict CHR in AL Amyloidosis

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis